Hepregen in the News
June, 2012 (Mass High Tech)
“Hepregen Gets $500K Grant” – Hepregen receives a $500,000 SBIR Phase 2B grant to further develop its liver model for drug development. Read More
June, 2011 (Life Science Leader)
"Drug Safety — Time For A Great Leap Forward?" Excerpt: Risk depends on knowledge. "Without accurate and predictive information about a drug, risk of 'false negatives' may be high," says Bernadette (Bonnie) Fendrock, president and CEO of Hepregen. Her company is developing a highly sensitive in vitro cellular model for preclinical testing to detect liver-toxicity signals in drug compounds. But Fendrock also sees the need for addressing safety on a wider front. “Although meaningful to each, the safety issue is addressed differently by various constituents: regulatory agencies and internally by scientists. In addition, top levels of management need to provide incentives for increasing safety just as they do for improving the drug pipeline." Read More
March 30, 2011 (Nature International weekly journal of science/nature.com)
"Tissue models: A living system on a chip" Nature 471,661–665 (31 March 2011) Excerpt: For years, scientists have struggled to reconstruct tissues and organs by combining cells and nanotechnology. These devices are now edging from cool concept to practical application. Read More
July 1, 2010 (Drug Metabolism and Disposition)
Wendy WeiWei Wang, Salman R. Khetani, Stacy Krzyzewski, David Duignan and R. Scott Obach. Assessment of a micropatterned hepatocyte coculture system to generate major human excretory and circulating drug metabolites. Drug Metabolism and Disposition, Vol. 38(10), p 1900-1905 (2010). Read More
April 2009 (Drug Discovery News)
"Putting Liver on a Chip" Read More
February 27, 2009 (Cell-Based Assay News)
"Battelle Ventures Spins Out Hepregen with $5M in Funding to Develop 'Microliver' Tox Platform" Read More
January 8, 2008 (Drug Discovery News)
"Honey, I shrunk the liver"
Excerpt: With liver toxicity looming as one of the main reasons pharmaceutical companies pull drugs off the market, the development of a technology to create tiny colonies of living human liver cells that model the full-sized organ should be welcome news to drug discovery and development professionals. MIT researchers recently reported that they had devised just such a technology, and believe their work could allow better screening of new drugs that are potentially harmful to the liver and may reduce the costs associated with their development.
Read More
Related Information
Featured Downloads
New Met ID Case Study Released
Ability of a Micropatterned Hepatocyte Co-culture System to Generate Major Human Drug Metabolites
Read MoreHepatoPac™-Kupffer Cell Inflammation Model
App. Note - A Micropatterned Hepatocyte-Kupffer Cell Co-culture System to Study Inflammation-Drug Interactions
Read More